Addition of the Aldose Reductase Inhibitor Benzofuroxane Derivative BF-5m to Prolonged and Moderate Exercise Training Enhanced Protection of the Rat Heart From Type-1 Diabetes.
QT interval
aldose-reductase
benzofuroxane
diabetes
exercise
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
12
2018
accepted:
29
03
2019
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
2
5
2019
Statut:
epublish
Résumé
Moderate exercise training may not be sufficient to exert beneficial effects on the cardiovascular system because of the long-term multifactorial etiology of diabetic complications. The addition of a proper pharmacological tool to the physical exercise should improve the outcomes of the diabetic damage. Here it is shown that 8 weeks exercise training of type 1 diabetic Sprague-Dawley (SD) rats resulted in a significantly increased heart rate, a 14% increase in the left ventricular ejection fraction (LVEF) increased plasma insulin levels and a 13% decrease in plasma glucose with respect to sedentary animals. The training also resulted in a 22% reduction in cardiac QT interval from a diabetic sedentary value of 185 ± 19 ms. Treatment of trained rats with the new antioxidant and NO-releasing aldose reductase 2 inhibitor 5(6)-(benzo[
Identifiants
pubmed: 31040781
doi: 10.3389/fphar.2019.00392
pmc: PMC6476970
doi:
Types de publication
Journal Article
Langues
eng
Pagination
392Références
Med Sci Sports Exerc. 2001 Dec;33(12):2053-7
pubmed: 11740298
Cardiovasc Res. 2002 Apr;54(1):162-74
pubmed: 12062372
Metabolism. 1992 Oct;41(10):1081-6
pubmed: 1328819
Diabetologia. 1992 May;35(5):414-8
pubmed: 1521721
J Gerontol A Biol Sci Med Sci. 2004 Nov;59(11):1089-98
pubmed: 15602054
Biochim Biophys Acta. 2005 Apr 15;1740(1):79-84
pubmed: 15878745
Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H10-23
pubmed: 21984538
Metabolism. 2012 Sep;61(9):1205-10
pubmed: 22465089
Int J Cardiol. 2012 Jun 14;157(3):422-4
pubmed: 22498422
J Membr Biol. 2013 Jan;246(1):47-55
pubmed: 23052826
J Med Chem. 2012 Dec 13;55(23):10523-31
pubmed: 23134227
Mediators Inflamm. 2012;2012:318621
pubmed: 23304060
Cardiovasc Res. 2013 Jul 1;99(1):55-64
pubmed: 23554460
PLoS One. 2013 Jul 29;8(7):e69954
pubmed: 23922868
Afr Health Sci. 2013 Dec;13(4):857-63
pubmed: 24940305
Biochem Soc Trans. 2014 Aug;42(4):928-33
pubmed: 25109981
Oxid Med Cell Longev. 2014;2014:908539
pubmed: 25143800
Eur J Pharmacol. 2014 Oct 15;741:186-94
pubmed: 25160740
J Med Chem. 2015 Mar 12;58(5):2047-67
pubmed: 25375908
Mediators Inflamm. 2014;2014:857958
pubmed: 25435715
PLoS One. 2014 Dec 31;9(12):e115970
pubmed: 25551214
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-20
pubmed: 26331889
Basic Res Cardiol. 2017 Jul;112(4):38
pubmed: 28534118
J Cell Physiol. 2019 Jun;234(6):8152-8161
pubmed: 30317615
Front Physiol. 2018 Sep 24;9:1307
pubmed: 30319436
Interact Cardiovasc Thorac Surg. 2019 Apr 1;28(4):607-612
pubmed: 30325425
Sports Med. 2019 Feb;49(2):255-268
pubmed: 30357657
Interv Med Appl Sci. 2018 Mar;10(1):59-63
pubmed: 30363341
Int J Mol Sci. 2018 Nov 15;19(11):null
pubmed: 30445764